RSP vs XBI
Invesco S&P 500 Equal Weight ETF vs SPDR S&P Biotech ETF
- • RSP has the lower expense ratio at 0.20% vs 0.35% for XBI.
- • RSP pays a higher dividend yield (1.46%).
Side-by-side metrics
| Metric | RSP | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.20% | 0.35% |
Dividend yield Trailing 12-month yield. | 1.46% | 0.35% |
AUM Assets under management — bigger funds are typically more liquid. | $100.66B | $10.92B |
YTD return | 16.71% | 28.80% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 0.80 | 1.01 |
P/E ratio | 20.31 | — |
Last price | $222.50 | $156.41 |
Inception | — | — |
Issuer | Invesco | State Street |
RSP top holdings
| MRNA | Moderna Inc | 0.32% |
| PTC | PTC Inc | 0.30% |
| ACN | Accenture PLC Class A | 0.29% |
| IT | Gartner Inc | 0.26% |
| HAS | Hasbro Inc | 0.26% |
| P | Everpure Inc Class A | 0.26% |
| MTD | Mettler-Toledo International Inc | 0.25% |
| CRL | Charles River Laboratories International Inc | 0.25% |
| CCL | Carnival Corporation Ltd | 0.25% |
| RVTY | Revvity Inc | 0.25% |
XBI top holdings
| MRNA | Moderna Inc | 2.37% |
| NTRA | Natera Inc | 1.82% |
| HALO | Halozyme Therapeutics Inc | 1.77% |
| TWST | Twist Bioscience Corp | 1.77% |
| BIIB | Biogen Inc | 1.75% |
| AMGN | Amgen Inc | 1.73% |
| EXEL | Exelixis Inc | 1.73% |
| UTHR | United Therapeutics Corp | 1.72% |
| ABBV | AbbVie Inc | 1.71% |
| GILD | Gilead Sciences Inc | 1.70% |
About RSP
RSP (Invesco S&P 500 Equal Weight ETF) is S&P 500 with each stock equally weighted. Managed by Invesco, the fund carries $100.7B in assets under management, an expense ratio of 0.20%, a dividend yield of 1.46%. Its largest holding is Moderna Inc (MRNA), which represents 0.3% of the portfolio. Real Estate is the fund's largest sector exposure at 5.8%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $10.9B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.35%. Its largest holding is Moderna Inc (MRNA), which represents 2.4% of the portfolio. Financial Services is the fund's largest sector exposure at 0.6%.